• Profile

Efficacy and safety of combination pharmacotherapy for patients with overactive bladder: A rapid evidence assessment

European Urology Nov 22, 2019

Gratzke C, Chapple C, Mueller ER, et al. - A literature search was carried out in June 2018 in order to assess the efficiency and safety of combination therapy in individuals with overactive bladder (OAB). Publications reported on clinical efficiency, safety, and health-associated quality of life (HRQoL) for mirabegron (M) plus solifenacin (S) from three 12-wk randomized controlled trials (RCTs)—SYMPHONY, SYNERGY, and BESIDE—and a 12-mo RCT, SYNERGY II. For individuals with OAB, mirabegron plus solifenacin gave efficient as well as well-endured treatment. Moreover, limited data for dual antimuscarinic therapy recommend an advantage in individuals with moderate-to-severe symptoms.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen